| Q58133954 | A human monoclonal antibody Fabreactive to oxidized LDL and carbamylated LDL recognizes human and mouse atherosclerotic lesions |
| Q38052020 | Advances in molecular imaging of atherosclerosis and myocardial infarction: shedding new light on in vivo cardiovascular biology. |
| Q37213081 | Candidate biomarkers for the detection of coronary plaque destabilization and rupture |
| Q57177626 | Comparison of I- and In-labeled peptide probes for in vivo detection of oxidized low-density lipoprotein in atherosclerotic plaques |
| Q36387263 | Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions |
| Q36687950 | Endothelial cells and macrophages, partners in atherosclerotic plaque progression. |
| Q39601696 | Human oxidation-specific antibodies reduce foam cell formation and atherosclerosis progression |
| Q56986839 | Identification of interleukin-2 for imaging atherosclerotic inflammation |
| Q34477436 | Imaging of Oxidation-Specific Epitopes in Atherosclerosis and Macrophage-Rich Vulnerable Plaques |
| Q34518372 | Imaging of oxidation-specific epitopes with targeted nanoparticles to detect high-risk atherosclerotic lesions: progress and future directions |
| Q35905632 | In vivo detection of oxidation-specific epitopes in atherosclerotic lesions using biocompatible manganese molecular magnetic imaging probes |
| Q28393314 | Inhaled diesel emissions alter atherosclerotic plaque composition in ApoE(-/-) mice |
| Q36681348 | Initiation and progression of atherosclerosis--enzymatic or oxidative modification of low-density lipoprotein? |
| Q30442045 | Molecular imaging in cardiovascular disease: Which methods, which diseases? |
| Q36141999 | Molecular imaging of atherosclerosis for improving diagnostic and therapeutic development |
| Q92424208 | Monoclonal antibody-based molecular imaging strategies and theranostic opportunities |
| Q38089761 | Nanotechnology in the diagnosis of atherosclerotic disease |
| Q27343116 | Near Infrared Fluorescence (NIRF) Molecular Imaging of Oxidized LDL with an Autoantibody in Experimental Atherosclerosis |
| Q39068959 | Near-infrared fluorescence imaging of murine atherosclerosis using an oxidized low density lipoprotein-targeted fluorochrome |
| Q35897012 | OxLDL-targeted iron oxide nanoparticles for in vivo MRI detection of perivascular carotid collar induced atherosclerotic lesions in ApoE-deficient mice |
| Q33857831 | Oxidation-specific epitopes as targets for biotheranostic applications in humans: biomarkers, molecular imaging and therapeutics |
| Q36385153 | Oxidized low-density lipoprotein biomarkers in atherosclerosis |
| Q49955253 | PET/MR Imaging of Malondialdehyde-Acetaldehyde Epitopes With a Human Antibody Detects Clinically Relevant Atherothrombosis |
| Q37438144 | Pre-clinical and clinical evaluation of nuclear tracers for the molecular imaging of vulnerable atherosclerosis: an overview |
| Q36239453 | Release and capture of bioactive oxidized phospholipids and oxidized cholesteryl esters during percutaneous coronary and peripheral arterial interventions in humans |
| Q41370572 | Targeted molecular probes for imaging atherosclerotic lesions with magnetic resonance using antibodies that recognize oxidation-specific epitopes |
| Q36090166 | Targeting the vulnerable plaque: the evolving role of nuclear imaging |
| Q38187881 | Visualizing the atherosclerotic plaque: a chemical perspective |